Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) CongressBusiness Wire • 06/09/23
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 06/08/23
A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than LaterThe Motley Fool • 06/07/23
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13Business Wire • 05/30/23
Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot MoreThe Motley Fool • 05/28/23
Vertex Pharmaceuticals Incorporated (VRTX) Presents at BofA Securities 2023 Health Care Conference (Transcript)Seeking Alpha • 05/13/23
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?The Motley Fool • 05/11/23
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett StockThe Motley Fool • 05/06/23